Categories

10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Please note

Note: The artciles are not research reports but assimilation of information available on public domain and it should not be treated as a research report.

Registration status with SEBI: I am not registered with SEBI under the (Research Analyst) regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”

Disclosure: It is safe to assume that I might have the dkiscussed companies in my portfolio and hence my point of view can be biased.Readers should consult registered consultants before making any investments
.

Archives : Old artciles

Saturday, May 30, 2009

Jupiter Bioscience Ltd:-Future growth prospects and outlook

Scripscan:Jupiter Bioscience Ltd
cmp:72
Traded in:Nse-bse

Story:With FY09 Revenues of Rs 143 crore (Rs 129 crore), after tax profits of Rs 32 crore (Rs 31 crore) and an EPS of Rs 19 this stock fetches a lowly PE of 3.7 and a dividend yield of roughly 3 per cent. Surprisingly FIIs which bought over a Rs 100 crore QIP placement a year ago at Rs 141 a share have been resilient and held on to the stock while the resident investors sold off the stock in early March 2009 to as low as Rs 25.So all those who think they have missed the run-up may still be proven wrong. After all it was only 2 years ago that in a much celebrated announcement Ranbaxy-then owned by the Singh family had taken a 14.9 per cent strategic stake in the corporate by subscribing to 32,00,000 warrants to be converted at Rs 147 a share. Post sale of Ranbaxy to Dai-Ichi no announcement has come about the conversion of warrants into Equity and the 20 per cent upfront payment made to Jupiter has been allowed to lapse.Still 47 lakh shares amounting to 29 per cent of the Equity of Jupiter continue to be held by FIIs led by ABN Amro (8.68 per cent), Macquarie Bank (6.61 per cent), Swiss Finance Corporation (4.65 per cent), HSBC (5.58per cent) and CLSA Mauritius (3.40 per cent), adding to the roughly 20 per cent stake of the promoters.Jupiter owns 6 plants in all, with 4 spread over in Andhra and Karnataka and one each in Switzerland and the US state of Maryland. Jupiter has been successful in winning a long term contract from Merck, Germany to supply peptide raw materials and intermediates manufactured by the company.This contract was won after a long process of validation of the technological capabilities and business processes by Merck compared to many other international players. Many leading pharmaceutical companies in Europe and USA have also begun sourcing their requirements from the company.Jupiter has made significant investments in upgrading its quality assurance system to meet the expectations of these international customers. Significant investments were also made in all the manufacturing facilities to upgrade and modernize the facilities and equip them to handle the new products being manufactured by the company. The analytical facilities and R&D Infrastructure systems in line with the growth in business. A major revamp in the unit which was acquired from Aurobindo Pharma Limited to make it suitable for manufacturing the peptide group of products has also been made.World wide peptides are being increasingly used as targets for therapeutics, vaccines, diagnostics and drug delivery systems. The trend is on the increase because of the inherent limitations of the small molecules to handle the growing complexity of diseases. The company is therefore provided continuous challenges in synthesizing the peptide building blocks to support the drug development industry.In 2010 the company expects to launch some of the generic peptide APIs in the unregulated market barring any unforeseen delays in regulatory. Further the company will also consolidate its position in the custom peptide synthesis work especially through the solid phase synthesis route from the US facility. The company is also planning to manufacture some organic APIs in the coming year the processes for manufacturing the same are under development.The fact remains Jupiter Bio will not fetch a miserly market cap of Rs 115 crore for too long. The prospects seem bright.A great buy at dips.

source:maverik

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
 
x

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner